Related Experiment Video
Updated: May 8, 2025
A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
Published on: July 25, 2022
Biomimetic Glyconanoparticle Nanoghost Vaccine Based on Red Blood Cells
Nofar Israel1, Shani Leviatan Ben-Arye1, Andrea Perota2
1Department of Cell Research and Immunology, The Shmunis School of Biomedicine and Cancer Research, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
Abstract:
Cancer vaccine is an active immunotherapy approach that aims to stimulate the host's immune responses toward specific targets on cancer cells, to direct their killing. Cancer cells commonly express aberrant cell surface glycosylation that support their immune evasion. Therefore, cancer glycosylation could be used as an efficient target for therapy. Lipid-based glyconanoparticles that express cancer glycosylation could mimic cancer cells and be used as therapeutic cancer vaccines. Here, we describe generation of biomimetic glyconanoparticles cancer vaccine based on porcine red blood cells that express cancer glycosylation containing the dietary nonhuman sialic acid N-glycolylneuraminic acid (Neu5Gc).
Insights
This study developed a novel cancer vaccine using biomimetic glyconanoparticles. These nanoparticles mimic cancer cells, targeting aberrant glycosylation to stimulate immune responses for cancer therapy.
Area of Science:
- Immunology
- Biotechnology
- Glycobiology
Background:
- Cancer cells exhibit altered glycosylation, aiding immune evasion.
- Aberrant cancer cell surface glycosylation presents a potential therapeutic target.
- Active immunotherapy, including cancer vaccines, aims to enhance host anti-cancer immunity.
Purpose of the Study:
- To develop biomimetic glyconanoparticles as a novel cancer vaccine strategy.
- To utilize cancer-specific glycosylation as a target for immunotherapy.
- To investigate the potential of lipid-based glyconanoparticles mimicking cancer cells.
Main Methods:
- Generation of biomimetic glyconanoparticles.
- Utilizing porcine red blood cells as a base material.
- Incorporating N-glycolylneuraminic acid (Neu5Gc) to mimic cancer glycosylation.
Main Results:
- Successful generation of glyconanoparticles expressing cancer-associated glycosylation.
- Demonstration of biomimetic particles capable of mimicking cancer cell surface features.
- Establishment of a novel platform for developing cancer vaccines.
Conclusions:
- Biomimetic glyconanoparticles offer a promising approach for cancer vaccine development.
- Targeting aberrant cancer glycosylation with nanoparticles can enhance immunotherapy.
- This strategy holds potential for effective cancer treatment by stimulating immune responses.
